rosiglitazone has been researched along with Nasopharyngeal Neoplasms in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, J; Hahn, SS; Tang, Q; Wu, J; Zhao, S; Zheng, F | 1 |
1 other study(ies) available for rosiglitazone and Nasopharyngeal Neoplasms
Article | Year |
---|---|
Repression of integrin-linked kinase by antidiabetes drugs through cross-talk of PPARγ- and AMPKα-dependent signaling: role of AP-2α and Sp1.
Topics: AMP-Activated Protein Kinases; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Metformin; Mutation; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; PPAR gamma; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Sp1 Transcription Factor; Thiazolidinediones; Transcription Factor AP-2 | 2014 |